To include your compound in the COVID-19 Resource Center, submit it here.

Coherus plans to resubmit BLA for Neulasta biosimilar

In its FY17 earnings, Coherus BioSciences Inc. (NASDAQ:CHRS) said it will resubmit a BLA for CHS-1701, with plans to launch the product in the U.S. next half. The company, which in November had

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers